Global Community

ZVRA Valuation: Sum-of-the-Parts (SOTP) AnalysisThe following is the step-by-step calculation chain for the ZVRA fair value. This utilizes a Sum-of-the-Parts (SOTP) architecture, as ZVRA consists of three distinct components, one of which has binary outcomes. All figures are in USD, based on Q1 2026 data.Why Sum-of-the-Parts, Not a Single MultipleA single forward-PE model collapses commercial earnings, cash, and the clinical pipeline into one generalized earnings number. This structurally forces an assumption that the pipeline succeeds entirely, rather than applying an appropriate probability weight. For a company where roughly a third of the value consists of binary (win-or-zero) clinical bets, a standard multiple is inadequate. Therefore, the three parts must be valued independently and summed.Part 1: The Commercial Business (Going Concern)Isolating sustainable operating profit from reported figures:Annualized revenue: ≈ 150M (MIPLYFFA commercial ~100M + royalties + EAP)Gross margin: >90%, less pipeline-directed R&D (counted separately in Part 3)Sustainable commercial operating profit: ≈ 50MAfter-tax: ≈ 42MFair multiple: 8–11x.Rationale: A single-product rare-disease annuity with patent protection to 2041 argues for a higher multiple. However, the market ceiling is already in sight (it covers roughly half of diagnosed NPC patients and added only 9 new prescriptions in the quarter), which caps the multiple. It is a long-duration income stream, not a growth compounder.Part 1 Value: 42M × 8.3 to 42M × 11.2 ≈ 350M – 470MCross-check: Discounting a flat 42M for 15 years (patent life) at 10% ≈ 320M floor. This is consistent with the multiple range.Part 2: Net Cash236.8M cash & investments − 0 long-term debt ≈ 237MThis is held separately and not consolidated inside an earnings multiple to prevent valuation distortion.Part 3: Risk-Adjusted Pipeline (rNPV)Each asset is valued as: (peak sales potential × probability of success × margin), discounted using a real options approach.AssetPhaseProbability of SuccessrNPV Estimatearimoclomol (EU/NPC)EMA reviewHigh (already US-approved)50M – 90Mceliprolol (vEDS)Phase 3~50% – 60%75M – 160MKP1077 (idiopathic hypersomnia/narcolepsy)Phase 3~40% – 55% (larger, competitive market)50M – 150MTotal175M – 400MThe wide range is deliberate; because these are binary outcomes, the variance is real and inherent to the assets, not a modeling weakness.Part 4: Summation and Per-Share ValueComponentBearBaseBullCommercial350M420M470MNet cash237M237M237MPipeline (rNPV)175M280M400MTotal value762M937M1,107M÷ ~61M diluted sharesFair value / share~$12.50~$15.40~$18.10Estimated Fair Value: ≈ $14 – $18, midpoint ≈ $15.50.Part 5: Sensitivity Analysis±10% on celiprolol's probability of success → ±~$0.70/share±30M on MIPLYFFA peak-sales assumption → ±~$3.00/shareThe discount rate has less impact here than in a standard DCF because the cash (Part 2) is not discounted, and the pipeline's variance is driven predominantly by clinical probabilities, not the discount rate.Valuation Variance and Dominant Swing VariablesThe valuation band is intentionally wide, and point-estimate confidence is inherently weaker due to the binary (win-or-zero) nature of the pipeline. The dominant swing variables are not the multiple or the discount rate; they are MIPLYFFA's ultimate NPC market penetration and the celiprolol Phase 3 readout. Those two factors alone can shift the fair value from approximately $12 to $24.Therefore, the definitive conclusion is not a static price target of $15.40. Rather, the going concern plus cash is worth roughly $10–$11 a share with reasonable confidence, while the remainder of the premium pays for a clinical option portfolio whose expected value is statistically real but carries enormous variance.Disclaimer: Informational analysis, not licensed financial advice.

Step 1 — Earnings Normalization (cleaning the input) Reported Q1 2026 net profit was 23.5M SAR, but it contained a non-cash loss of 13.3M from fair-value revaluation of derivative instruments. Stripping that out: Normalized Q1 2026 profit = 23.5 + 13.3 ≈ 36.8M SAR This is the single most important step. Garbage in, garbage out — any multiple applied to the polluted 23.5M figure would have produced a fake fair value. Step 2 — Annualizing with seasonal adjustment I did not simply multiply 36.8 × 4 = 147M, because Q1 was the seasonal trough (Ramadan + Eid suppressed elective procedures). Q1 2025 normalized was 51.1M while full-year 2025 delivered 200.4M — meaning Q1 historically contributes roughly 25% or slightly less of the year. Applying a similar seasonal pattern, plus partial recovery of the new centers' occupancy through the year: FY2026E normalized earnings ≈ 170–200M SAR EPS range = 170/44.3 to 200/44.3 = 3.84 – 4.51 SAR Step 3 — Multiple selection (the judgment call) Saudi healthcare peers trade roughly between ~20x (mature operators) and ~35x+ (premium growth like Al Habib). Almoosa sits below the premium tier: mid-cap, single-region, currently in margin compression. I assigned a fair P/E band of 24–28x — a discount to the sector leaders, a premium to no-growth operators. Method 1 (Comps): 3.84 × 24 = 92 → 4.51 × 28 = 126 SAR Step 4 — Forward exit value (capturing the expansion) Method 1 punishes the company for facilities that consume costs today but produce revenue tomorrow. So Method 2 values the completed platform: Assumption: third Al-Ahsa center + new Khobar specialist hospital lift bed capacity by roughly half, gross margin reverts to ~31%. Projected FY2028 normalized profit: 280–320M SAR → EPS 6.3–7.2. Exit multiple: 26x (midpoint of the fair band, since by 2028 it's a proven grower). Exit value (2028) = 6.3×26 to 7.2×26 ≈ 164 – 188 SAR Step 5 — Discounting to present value Discount rate: 9.5% — a cost-of-equity proxy built roughly as: Saudi risk-free ~5% + equity risk premium ~5.5% × beta ~0.8 for a defensive healthcare operator. Discount period: 2 years (mid-2026 → mid-2028). PV = Exit value / (1.095)² = 164/1.199 to 188/1.199 ≈ 137 – 157 SAR Step 6 — Triangulation (weighting the methods) MethodRangeWeightRationaleNormalized comps92–126~30%Real but punishes transition yearDiscounted exit multiple137–157~50%Best fits an expansion-phase assetStreet target169–192~20%Single-analyst coverage, low reliability Weighted blend → fair value ≈ 140–155 SAR, midpoint ~148. Step 7 — Sensitivity (the honesty layer) The output's fragility, quantified: ±1 point on the P/E multiple → ±~4.5 SAR on fair value ±10M SAR on the earnings estimate → ±~6 SAR ±1% on the discount rate → ±~3 SAR on the Method-2 leg So the defensible claim is never "the stock is worth 148.00" — it's "fair value clusters in the 140s under reasonable assumptions, and the dominant swing variable is gross margin recovery, not the discount rate." One final point of intellectual honesty: Steps 2, 3, and 4 each contain a judgment of mine (seasonality pattern, multiple band, 2028 earnings power). A different analyst with equally defensible inputs could land at 120 or at 170. That's not a flaw of this model specifically — it's the nature of valuation. The method's value isn't the point estimate; it's that it forces every disagreement into a specific, testable assumption you can monitor quarter by quarter.